# Neuphoria Therapeutics Inc.: financial statements, quarterly

NEUP · Nasdaq · CIK 1191070 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/neup.md) · [Financials](/companies/neup/financials.md) · [Filings](/companies/neup/filings.md) · [Insiders](/companies/neup/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/neup/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | [0.7](/filings/0001193125-26-054509.md) | [15.0](/filings/0001193125-26-225442.md) | [(0.0) d](/filings/0001193125-25-223338.md) | not reported | not reported | not reported | not reported |
| Research and development | $m | [3.1](/filings/0000950170-24-127032.md) | [2.0](/filings/0000950170-25-020473.md) | [1.2](/filings/0000950170-25-075175.md) | [3.1 d](/filings/0001193125-25-223338.md) | [1.9](/filings/0001193125-25-281579.md) | [1.7](/filings/0001193125-26-054509.md) | [1.6](/filings/0000950170-25-075175.md) | [3.8 d](/filings/0001193125-25-223338.md) | [3.8](/filings/0001193125-25-281579.md) | [0.7](/filings/0001193125-26-054509.md) | not reported | not reported |
| Operating income | $m | [(5.5)](/filings/0000950170-24-127032.md) | [(4.6)](/filings/0000950170-25-020473.md) | [(2.4)](/filings/0000950170-25-075175.md) | [(5.5) d](/filings/0001193125-25-223338.md) | [(3.6)](/filings/0001193125-25-281579.md) | [(3.7)](/filings/0001193125-26-054509.md) | [12.0](/filings/0001193125-26-225442.md) | [(5.8) d](/filings/0001193125-26-395536.md) | [(5.7)](/filings/0001193125-25-281579.md) | [(4.1)](/filings/0001193125-26-054509.md) | [(1.2)](/filings/0001193125-26-225442.md) | [(5.5) d](/filings/0001193125-26-395536.md) |
| Income tax | $m | [(0.0)](/filings/0000950170-24-127032.md) | [(0.0)](/filings/0000950170-25-020473.md) | [0.0](/filings/0000950170-25-075175.md) | [(0.0) d](/filings/0001193125-25-223338.md) | [(0.1)](/filings/0001193125-25-281579.md) | [0.0](/filings/0001193125-26-054509.md) | [(0.1)](/filings/0001193125-26-225442.md) | [(0.3) d](/filings/0001193125-26-395536.md) | [(0.0)](/filings/0001193125-25-281579.md) | [(0.0)](/filings/0001193125-26-054509.md) | [(0.0)](/filings/0001193125-26-225442.md) | [(0.0) d](/filings/0001193125-26-395536.md) |
| Net income | $m | [(5.5)](/filings/0000950170-25-075175.md) | [(4.6)](/filings/0000950170-25-075175.md) | [(2.8)](/filings/0000950170-25-075175.md) | [(2.7) d](/filings/0001193125-25-223338.md) | [(0.8)](/filings/0001193125-26-225442.md) | [(1.9)](/filings/0001193125-26-225442.md) | [11.3](/filings/0001193125-26-225442.md) | [(8.9) d](/filings/0001193125-26-395536.md) | [(9.9)](/filings/0001193125-26-225442.md) | [1.9](/filings/0001193125-26-225442.md) | [(0.5)](/filings/0001193125-26-225442.md) | [(4.9) d](/filings/0001193125-26-395536.md) |
| Diluted EPS | $ per share | [0.00](/filings/0000950170-24-127032.md) | [(5.31)](/filings/0000950170-25-020473.md) | [(2.83)](/filings/0000950170-25-075175.md) | not reported | [(0.62)](/filings/0001193125-25-281579.md) | [(1.79)](/filings/0001193125-26-054509.md) | [6.55](/filings/0001193125-26-225442.md) | not reported | [(4.41)](/filings/0001193125-25-281579.md) | [(0.77)](/filings/0001193125-26-054509.md) | [(0.09)](/filings/0001193125-26-225442.md) | not reported |
| Basic EPS | $ per share | [0.00](/filings/0000950170-24-127032.md) | [(5.31)](/filings/0000950170-25-020473.md) | [(2.83)](/filings/0000950170-25-075175.md) | not reported | [(0.62)](/filings/0001193125-25-281579.md) | [(1.23)](/filings/0001193125-26-054509.md) | [6.55](/filings/0001193125-26-225442.md) | not reported | [(4.41)](/filings/0001193125-25-281579.md) | [0.41](/filings/0001193125-26-054509.md) | [(0.09)](/filings/0001193125-26-225442.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.1](/filings/0000950170-24-127032.md) | [10.2](/filings/0000950170-25-020473.md) | [8.4](/filings/0000950170-25-075175.md) | [12.6](/filings/0001193125-25-223338.md) | [8.1](/filings/0001193125-25-281579.md) | [4.3](/filings/0001193125-26-054509.md) | [17.0](/filings/0001193125-26-225442.md) | [14.2](/filings/0001193125-26-395536.md) | [13.6](/filings/0001193125-25-281579.md) | [22.2](/filings/0001193125-26-054509.md) | [19.4](/filings/0001193125-26-225442.md) | [19.9](/filings/0001193125-26-395536.md) |
| Current assets | $m | not reported | not reported | not reported | [13.2](/filings/0001193125-25-223338.md) | [8.4](/filings/0000950170-24-127032.md) | [4.4](/filings/0000950170-25-020473.md) | [17.1](/filings/0000950170-25-075175.md) | [15.0](/filings/0001193125-26-395536.md) | [14.0](/filings/0001193125-25-281579.md) | [23.4](/filings/0001193125-26-054509.md) | [21.7](/filings/0001193125-26-225442.md) | [21.1](/filings/0001193125-26-395536.md) |
| Total assets | $m | not reported | not reported | not reported | [27.6](/filings/0001193125-25-223338.md) | [22.9](/filings/0000950170-24-127032.md) | [18.2](/filings/0000950170-25-020473.md) | [30.7](/filings/0000950170-25-075175.md) | [28.6](/filings/0001193125-26-395536.md) | [27.3](/filings/0001193125-25-281579.md) | [36.6](/filings/0001193125-26-054509.md) | [34.8](/filings/0001193125-26-225442.md) | [28.7](/filings/0001193125-26-395536.md) |
| Current liabilities | $m | not reported | not reported | not reported | [3.8](/filings/0001193125-25-223338.md) | [2.6](/filings/0000950170-24-127032.md) | [2.1](/filings/0000950170-25-020473.md) | [1.6](/filings/0000950170-25-075175.md) | [4.2](/filings/0001193125-26-395536.md) | [5.1](/filings/0001193125-25-281579.md) | [2.6](/filings/0001193125-26-054509.md) | [1.5](/filings/0001193125-26-225442.md) | [0.8](/filings/0001193125-26-395536.md) |
| Total liabilities | $m | not reported | not reported | not reported | [10.2](/filings/0001193125-25-223338.md) | [5.8](/filings/0000950170-24-127032.md) | [4.4](/filings/0000950170-25-020473.md) | [4.7](/filings/0000950170-25-075175.md) | [9.6](/filings/0001193125-26-395536.md) | [14.8](/filings/0001193125-25-281579.md) | [6.9](/filings/0001193125-26-054509.md) | [5.4](/filings/0001193125-26-225442.md) | [4.1](/filings/0001193125-26-395536.md) |
| Shareholders' equity | $m | [17.2](/filings/0000950170-25-075175.md) | [19.5](/filings/0000950170-25-075175.md) | [17.9](/filings/0000950170-25-075175.md) | [17.5](/filings/0001193125-26-395536.md) | [17.1](/filings/0001193125-26-225442.md) | [13.7](/filings/0001193125-26-225442.md) | [26.0](/filings/0001193125-26-225442.md) | [19.0](/filings/0001193125-26-395536.md) | [12.5](/filings/0001193125-26-225442.md) | [29.7](/filings/0001193125-26-225442.md) | [29.4](/filings/0001193125-26-225442.md) | [24.6](/filings/0001193125-26-395536.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.4)](/filings/0000950170-24-127032.md) | [(3.9) d](/filings/0000950170-25-020473.md) | [(3.3) d](/filings/0000950170-25-075175.md) | [(3.0) d](/filings/0001193125-25-223338.md) | [(4.4)](/filings/0001193125-25-281579.md) | [(3.4) d](/filings/0001193125-26-054509.md) | [11.5 d](/filings/0001193125-26-225442.md) | [(3.6) d](/filings/0001193125-26-395536.md) | [(3.8)](/filings/0001193125-25-281579.md) | [(6.4) d](/filings/0001193125-26-054509.md) | [(3.3) d](/filings/0001193125-26-225442.md) | [1.2 d](/filings/0001193125-26-395536.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,496](/filings/0000950170-24-127032.md) | [0.9](/filings/0000950170-25-020473.md) | [1.0](/filings/0000950170-25-075175.md) | [1.3](/filings/0001193125-25-281579.md) | [1.6](/filings/0001193125-26-054509.md) | [1.7](/filings/0001193125-26-225442.md) | [2.2](/filings/0001193125-25-281579.md) | [4.5](/filings/0001193125-26-054509.md) | [5.4](/filings/0001193125-26-225442.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,411,334 at 2026-09-17, from the cover of the [10-K filed 2026-09-18](/filings/0001193125-26-395536.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.